Limitations and uncertainty all over telehealth reimbursement have always been an impediment to adoption. During the COVID-19 crisis, that stress was eased fairly, but now the new normal is starting up to consider form. What limitations even now keep on being to telehealth reimbursement, and how may they be prevail over? To reply that concern, host Jonah Comstock and Health care Finance Information Handling Editor Susan Morse welcome McKinsey & Corporation associates Oleg Bestsennyy and Gunjan Khanna.

This episode is brought to you by BlueJeans.

Like what you hear? Subscribe to the podcast on Apple Podcasts, Spotify or Google Perform!


Chatting factors:

  • COVID-19 reimbursement modifications and which of them will stick all over
  • Adoption lessons acquired and how they’ll influence reimbursement coverage
  • Holistic tele-treatment and treatment further than the movie pay a visit to
  • Impact of new entrants and innovation on the space
  • Is charge-for-support reimbursement an innovation blocker?
  • Reimbursement for diverse telehealth modalities
  • Time to guide somewhat than stick to for personal payers?
  • The even now-unresolved concern of induced utilization
  • The increase of worth-centered treatment and hybrid treatment designs
  • Telehealth reimbursement and wellness equity
  • How are individuals feeling about telehealth now?
  • Last views: the upcoming of telehealth reimbursement

Additional about this episode:

Report demonstrates ‘vast improvement’ in condition telehealth reimbursement guidelines

COVID-19 might completely alter the telehealth landscape, from reimbursement to utilization

Telehealth reimbursement parity spurs insurance provider fears of overutilization

CMS will reimburse for 11 new telehealth products and services during the community wellness crisis

Congressional motion is essential for telehealth not to return to a rural gain, Seema Verma says

Telehealth: A quarter-trillion-dollar write-up-COVID-19 reality? (McKinsey)

COVID-19 Customer Health care Insights: What 2021 might hold (McKinsey)

How COVID-19 has modified the way US buyers consider about healthcare (McKinsey)